Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola
批准号:
10579086
负责人:
Robert F Garry
金额:
$7.5万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-01 至 2023-01-31
关键词:
AchievementAffectAfricaAfricanAntibodiesAreaBasic ScienceCessation of lifeClinicalClinical ResearchCollaborationsComplementComputational BiologyComputer ModelsData SetDevelopmentDiseaseDisease OutbreaksDisease OutcomeEbolaEbola Hemorrhagic FeverEbola virusEpidemicEuropeEvolutionExposure toGenomicsGeographyGoalsGovernmentHLA AntigensHospital AdministrationHospitalsHourHumanImmunologyIncidenceIndividualInfectionIntegration Host FactorsLassa FeverLassa virusMachine LearningMetabolicMethodsMolecularNigeriaNorth AmericaOutcomePatient-Focused OutcomesPatientsPhysiologicalPopulationProteomicsProvincePublic HealthResearchRodentRoleSamplingSierra LeoneStatistical MethodsStatistical ModelsStructureSurvivorsSystemSystems BiologyT-LymphocyteTestingTherapeuticTimeVaccinesViralViral Hemorrhagic FeversVirusVirus Diseasescohortexperienceimprovedinfection managementmembermultidisciplinarynovelpredictive modelingpredictive testpreventprogramsrole modelvirologyweapons
中文摘要
项目概要/摘要
塞拉利昂的东部省是世界上拉沙热发病率最高的地区。 议员
一个研究小组已经在凯内马政府医院(KGH)研究拉沙热超过12年
年 2013-16年西非埃博拉疫情开始于距离KGH不到四小时车程的地方,
第一次埃博拉疫情发生在靠近现有病毒性出血热基础设施的地区,
临床研究 KGH每年管理多达600名疑似拉沙热患者,凯内马和
周边地区出现大量埃博拉病例。我们将利用现有的样本,
建立了感染拉沙热或埃博拉病毒的人类队列。 虽然众所周知,
拉沙热和埃博拉病毒都有无症状或轻度症状的感染,但不清楚哪种宿主
这些因素决定了暴发性出血热的进展。 同样,拉萨的大部分地区
发烧和埃博拉幸存者会产生大量严重的后遗症,但预测这些后遗症的因素
并发症仍然难以捉摸。 我们的研究项目支持拉沙热和埃博拉幸存者团体。
我们建议结合实验方法和计算建模来测试和验证
拉沙热和埃博拉的重要性假说。我们的团队有着良好的合作记录,
在拉沙病毒和埃博拉病毒方面具有独特的专门知识,并有适当的多学科代表,
系统和计算生物学,病毒学,免疫学,基因组学,蛋白质组学,机器学习,
执行拟议计划所需的统计方法和建模。项目1的总体目标是
生成可用于建立拉沙热患者结局预测模型的综合数据集
还有埃博拉病毒 根据具体目标1提出的研究将定义区分Lassa的生理属性
发烧和埃博拉幸存者和非幸存者,以及出现严重后遗症的个人。具体目标2
将阐明埃博拉和拉沙热幸存者成功抗体网络的演变和功能。不
细胞动力学和人类白细胞抗原在成功清除埃博拉病毒中的作用,
拉沙病毒将在具体目标3中描述的研究中定义。在具体目标4中,我们将开发和测试
宿主因素在拉沙热和埃博拉预后中作用的预测模型。 关于东道因素的项目1
补充了项目2中描述的关于病毒因子的研究,并整合和利用了
丹
英文摘要
Project Summary / Abstract
The Eastern Province of Sierra Leone has the world’s highest incidence of Lassa fever. Members of this
research team have been working on Lassa fever at the Kenema Government Hospital (KGH) for over twelve
years. The 2013-16 West African Ebola epidemic began less than a four-hour drive from KGH and was the
first Ebola outbreak to occur in an area close to an existing facility for viral hemorrhagic fever basic and
clinical research. KGH manages up to 600 suspected Lassa fever patients per year, and Kenema and
surrounding districts experienced a large number of Ebola case. We will leverage existing samples from these
established cohorts of humans infected with Lassa fever or Ebola. While it is well established that
asymptomatic or mildly symptomatic infections occur in both Lassa fever and Ebola, it is unknown which host
factors determine the progression to fulminant hemorrhagic fever. Likewise, a substantial portion of Lassa
fever and Ebola survivors develop a plethora of serious sequelae, but factors that predicate these
complications remain elusive. Our research program supports both Lassa fever and Ebola survivor groups.
We propose to integrate experimental approaches and computational modeling to test and validate
hypotheses of significance to Lassa fever and Ebola. Our assembled team has a track record of collaboration,
unique expertise with both Lassa virus and Ebola virus and the appropriate multidisciplinary representation in
systems and computational biology, virology, immunology, genomics, proteomics, machine learning,
statistical methods and modeling required to execute the proposed program. Our overall goal in Project 1 is to
generate an integrated dataset that can be used to build predictive models of patient outcomes in Lassa fever
and Ebola. Studies proposed under Specific Aim 1 will define physiological attributes that distinguish Lassa
fever and Ebola survivors and non-survivors, and individuals that develop serious sequelae. Specific Aim 2
will elucidate the evolution and function of successful antibody networks in Ebola and Lassa fever survivors. T
cell dynamics and the role human leukocyte antigens leading to successful clearance of Ebola virus and
Lassa virus will be defined in studies described in Specific Aim 3. In Specific Aim 4 we will develop and test
predictive models for the role of host factors in Lassa fever and Ebola outcome. Project 1 on host factors
complements the studies described in Project 2 on viral factors and integrates with and utilizes each of the
Cores.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails
-
批准号:10158449
-
项目类别:
-
资助金额:$183.19万
-
财政年份:2019
-
负责人:Robert F Garry
-
依托单位:
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails
-
批准号:10402339
-
项目类别:
-
资助金额:$165.87万
-
财政年份:2019
-
负责人:Robert F Garry
-
依托单位:
Preclinical Evaluation of Advanced Pan-Lassa Immunotherapeutic Cocktails
-
批准号:10617738
-
项目类别:
-
资助金额:$165.87万
-
财政年份:2019
-
负责人:Robert F Garry
-
依托单位:
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola
-
批准号:10374719
-
项目类别:
-
资助金额:$42.5万
-
财政年份:2018
-
负责人:Robert F Garry
-
依托单位:
Project 1
-
批准号:10558423
-
项目类别:
-
资助金额:$88.45万
-
财政年份:2018
-
负责人:Robert F Garry
-
依托单位:
Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola
-
批准号:10310605
-
项目类别:
-
资助金额:$10.54万
-
财政年份:2018
-
负责人:Robert F Garry
-
依托单位:
Structure-based design of novel Lassa virus glycoproteins for vaccine development
-
批准号:10202410
-
项目类别:
-
资助金额:$117.29万
-
财政年份:2017
-
负责人:Robert F Garry
-
依托单位:
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail
-
批准号:9926211
-
项目类别:
-
资助金额:$110.85万
-
财政年份:2017
-
负责人:Robert F Garry
-
依托单位:
Preclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktail
-
批准号:10176382
-
项目类别:
-
资助金额:$112.42万
-
财政年份:2017
-
负责人:Robert F Garry
-
依托单位:
Structure-based design of novel Lassa virus glycoproteins for vaccine development
-
批准号:10438220
-
项目类别:
-
资助金额:$14.37万
-
财政年份:2017
-
负责人:Robert F Garry
-
依托单位:
Structure-based design of novel Lassa virus glycoproteins for vaccine development
-
批准号:10356645
-
项目类别:
-
资助金额:$3.62万
-
财政年份:2017
-
负责人:Robert F Garry
-
依托单位:
International Collaboration in Infectious Disease Research on Lassa fever
-
批准号:9012762
-
项目类别:
-
资助金额:$77.03万
-
财政年份:2015
-
负责人:Robert F Garry
-
依托单位:
Antibody immunotherapeutics for biodefense against Lassa virus
-
批准号:8793681
-
项目类别:
-
资助金额:$101.0万
-
财政年份:2013
-
负责人:Robert F Garry
-
依托单位:
Antibody immunotherapeutics for biodefense against Lassa virus
-
批准号:8474396
-
项目类别:
-
资助金额:$133.77万
-
财政年份:2013
-
负责人:Robert F Garry
-
依托单位:
Opening a New Lassa Fever Ward in Kenema Sierra Leone
-
批准号:8459184
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2013
-
负责人:Robert F Garry
-
依托单位:
Antibody immunotherapeutics for biodefense against Lassa virus
-
批准号:9211282
-
项目类别:
-
资助金额:$114.85万
-
财政年份:2013
-
负责人:Robert F Garry
-
依托单位:
Preclinical development of recombinant antigen diagnostics for Lassa fever
-
批准号:8248226
-
项目类别:
-
资助金额:$131.61万
-
财政年份:2009
-
负责人:Robert F Garry
-
依托单位:
Preclinical development of recombinant antigen diagnostics for Lassa fever
-
批准号:8055356
-
项目类别:
-
资助金额:$133.54万
-
财政年份:2009
-
负责人:Robert F Garry
-
依托单位:
Preclinical development of recombinant antigen diagnostics for Lassa fever
-
批准号:8458569
-
项目类别:
-
资助金额:$123.72万
-
财政年份:2009
-
负责人:Robert F Garry
-
依托单位:
Preclinical development of recombinant antigen diagnostics for Lassa fever
-
批准号:7645356
-
项目类别:
-
资助金额:$149.96万
-
财政年份:2009
-
负责人:Robert F Garry
-
依托单位:
海外基金